Cirtuvivint
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 and ASTX727 + Venetoclax in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 54 patients (estimated)
- Sponsors
- National Cancer Institute (NCI)
- Tags
- CLK Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 2036
- NCT Identifier
- NCT06484062
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.